Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at Upcoming March Conferences

MADISON, Wis., March 05, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
February 08, 2018 08:15 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference

MADISON, Wis., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
February 07, 2018 08:15 ET | Source: Cellectar Biosciences, Inc.

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

MADISON, Wis., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
January 29, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers

MADISON, Wis., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
January 22, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference

MADISON, Wis., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
January 04, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate at Biotech Showcase 2018

MADISON, Wis., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
December 14, 2017 08:43 ET | Source: Cellectar Biosciences, Inc.

Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers

MADISON, Wis., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
December 06, 2017 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131

MADISON, Wis., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
November 20, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event

Madison, Wis., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
November 09, 2017 16:01 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance

MADISON, Wis., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today reported financial...